Receptor signaling: When dimerization is not enough

Current Biology

Volumn 9, Issue 15, 1999, Pages

  Jiang, Guoqiang ^a   Hunter, Tony ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0033615077     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(99)80357-1     Document Type: Note

References (25)

1. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213-223.
2. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, YOu Y, Liu KD, Goldsmith MA, He W, Krause CD, et al.: An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 1998, 5:993-1004.
3. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 å. Science 1996, 273:464-471.
4. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA: Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283:987-990.
5. Remy I, Wilson IA, Michnick SW: Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999, 283:990-993.
6. neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 1997, 14:687-696.
7. Burke CL, Stern DF: Activation of neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol 1998, 18:5371-5379.
8. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 1989, 339:230-231.
9. Smith SO, Smith CS, Bormann BJ: Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat Struct Biol 1996, 3:252-258.
10. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chrino AJ, Zhang J, et al.: Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
11. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G: Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem 1996, 271:24691-24697.
12. Watowich SS, Hilton DJ, Lodish HF: Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol Cell Biol 1994, 14:3535-3549.
13. Kossiakoff AA, De Vos AM: Structural basis for cytokine hormone-receptor recognition and receptor activation. Adv Protein Chem 1998, 52:67-108.
14. Alexander WS, Metcalf D, Dunn AR: Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995, 14:5569-5578.
15. Sternberg MJ, Gullick WJ: A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng 1990, 3:245-248.
16. Van Obberghen E: Signalling through the insulin receptor and the insulin-like growth factor-I receptor. Diabetologia 1994, 37:S125-134.
17. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR: Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995, 270:13303-13307.
18. Naismith JH, Devine TQ, Kohno T, Sprang SR: Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 1996, 4:1251-1262.
19. Jiang Y, Woronicz JD, Liu W, Goeddel DV: Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999, 283:543-546.
20. Chervitz SA, Falke JJ: Molecular mechanism of transmembrane signaling by the aspartate receptor: A model. Proc Natl Acad Sci USA 1996, 93:2545-2550.
21. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J: Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 1996, 35:1681-1691.
22. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, Livnah O, Wrighton NC, Middleton SA, Loughney DA, et al.: Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998, 37:3699-3710.
23. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464.
24. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tanski RL, Mattheakis LC, Boytos CM et al.: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276:1696-1699.
25. Tian SS, Lamb P, King AG, Miller SG, KessLer L, Luengo JI, AveriLL L, Johnson RK, Gleason JG, Pelus LM, et al.: A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998, 281:257-259.